Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Rhabdoid Tumor 1Pancreatic Adenocarcinoma 1Neoplasms 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Esophageal Neoplasms 1Endometrial Neoplasms 1Chordoma 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Advanced Liver Cancers 1

Interventions

pembrolizumab 20Paclitaxel 13Fluorouracil 13Docetaxel 13Radiotherapy 12Oxaliplatin 11Cisplatin 11Capecitabine 8Carboplatin 7Leucovorin 6Cetuximab 5Nivolumab 4Albumin-Bound Paclitaxel 4atezolizumab 3Trastuzumab 3Ramucirumab 3Irinotecan 3Interleukin-2 3Injections 3Epirubicin 3Drug Therapy 3Dexamethasone 3130-nm albumin-bound paclitaxel 3tremelimumab 2tisotumab vedotin 2regorafenib 2patritumab deruxtecan 2oblimersen 2nedaplatin 2lenvatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Esophageal Neoplasms × Tiragolumab × Clear all
NCT03281369 2025-12-15

A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)

Hoffmann-La Roche

Phase 1/2 Completed
214 enrolled
Gastrointestinal

Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡